Commentary Open Access
Volume 2 | Issue 2 | DOI: https://doi.org/10.33696/cancerimmunol.2.013
Protein Therapeutics from Monolayer to Spheroids- A Model for Preclinical Investigations
Neha Arora1,*, Siddhartha Sankar Ghosh1,2,*
- 1Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati-781039, Assam, India
- 2Centre for Nanotechnology, Indian Institute of Technology Guwahati, Guwahati-781039, Assam, India
Corresponding Author
Neha Arora, n.arora@alumni.iitg.ac.in
Siddhartha Sankar Ghosh, sghosh@iitg.ac.in
Received Date: March 27, 2020
Accepted Date: May 12, 2020
Arora N, Ghosh SS. Protein Therapeutics from Monolayer to Spheroids- A Model for Preclinical Investigations. J Cancer Immunol. 2020; 2(2): 40-43.
Copyright: © 2020 Arora N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Protein Therapeutics from Monolayer to Spheroids- A Model for Preclinical Investigations
The arrival of recombinant insulin in the pharmaceutical market paved a new direction for the clinical potential of proteins. Thus, the pharmaceutical industry underwent a paradigm shift towards proteins as therapeutic moieties. A number of recombinant protein drugs are available and many more are in pipeline to target major diseases, such as cancer, viral diseases, cardiovascular diseases and endocrine disease.
The Potential of Combination Therapies and Patient Stratification to Improve CCR2 Inhibition Therapeutics
Chemokines and their receptors are the communication mechanism used by cells of the immune system, allowing them to identify and eliminate pathogens and cancerous cells. However, it is becoming clear that chemokines and their receptors are also playing a role in tumor progression and metastasis. An example of such coopting is the CCL2-CCR2 axis.
Repurposed Anti-IL-6 Therapeutics, Another Way to Quell the Cytokine Storm in Tuberculosis
Study on ‘‘cytokine storms’’ has been braced up in infectious diseases. The pertinence of this research begins to be evident in tuberculosis as it was observed that increased levels of Interleukin-6 (IL-6) were connected with disease severity. The IL-6 blockers therapeutics approaches for tuberculosis are currently a key line of research, with many in progress clinical trials, as IL-6 has become an important factor of the immune response to tuberculosis.
Treatment of Traumatic Brain Injury: Nanotherapeutics
Nanotechnology and regenerative nanotherapeutics enrich the renewing features and function of the diseased cells and tissue by replenishing the local environment, while inhibiting further degeneration. These featured therapeutics perform cell maintenance and promote cellular events to develop better communication between re-forming molecules of remedies and the brain.
Protein Assembly Modulation: A New Approach to Amyotrophic Lateral Sclerosis (ALS) Therapeutics
Amyotrophic Lateral Sclerosis (ALS) is a devastating and progressive neurodegenerative disease with a complex, multifactorial pathophysiology, culminating in death of motor neurons. We introduce a new mechanism of ALS pathogenesis via study of a novel drug-like small molecule series that targets a subset of protein disulfide isomerase (PDI) within a previously largely unappreciated transient and energy-dependent multi-protein complex enriched for proteins of the ALS interactome. This drug, found by a novel phenotypic screen, has activity in cellular models for both familial and sporadic ALS, as well as in transgenic worms, flies, and mice bearing a diversity of human genes with ALS-associated mutations.